Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 5/20 | 0.39 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 11/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 8/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048671 | 0.87 | SREBF2 (0.42) | SREBF2SREBF1KLKB1PDE10AKLK1 | |
| SCHEMBL5045028 | 0.87 | SREBF2 (0.41) | SREBF2SREBF1KLKB1PDE10AKLK1 | |
| SCHEMBL5039865 | 0.86 | SREBF2 (0.43) | SREBF2SREBF1KLKB1PDE10AKLK1 | |
| SCHEMBL5040218 | 0.86 | SREBF2 (0.43) | SREBF2SREBF1PDE10AALDH1A1L3MBTL1 | |
| SCHEMBL5044843 | 0.85 | ALDH1A1 (0.45) | SREBF2SREBF1KLKB1PDE10AKLK1 | |
| SCHEMBL5043975 | 0.82 | KLKB1 (0.46) | SREBF2SREBF1KLKB1KLK1ALDH1A1 | |
| SCHEMBL5133244 | 0.82 | KLKB1 (0.40) | SREBF2SREBF1KLKB1KLK1 | |
| SCHEMBL5039299 | 0.82 | EIF4E (0.41) | SREBF2SREBF1ALDH1A1 | |
| SCHEMBL5047645 | 0.79 | SREBF2 (0.42) | SREBF2SREBF1KLKB1PDE10AKLK1 | |
| SCHEMBL5045669 | 0.79 | HTR2A (0.43) | SREBF2SREBF1KLKB1PDE10AKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583762-B1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7135488-B2 | Pyrrolyl-thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1583762-A1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004060888-A1 | NOVEL CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | CNR1, CNR2, NPY1R | SREBF2 2076/4885SREBF1 1307/4885KLKB1 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.